Last updated: November 15, 2023
Sponsor: Nanjing First Hospital, Nanjing Medical University
Overall Status: Active - Not Recruiting
Phase
4
Condition
Gastroparesis
Gastrointestinal Diseases And Disorders
Irritable Bowel Syndrome (Ibs)
Treatment
Placebo
DAO supplement
Clinical Study ID
NCT06139744
KY20230915-01
Ages 18-65 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- Age 18-65 years old;
- Diagnosed with IBS according to Rome IV diagnostic criteria; Recurrent abdominal painoccurred on an average of at least 1 day per week in the past 3 months and wasassociated with two or more of the following criteria: i. Related to defecation; ii.Associated with changes in bowel frequency; iii. Correlated with fecal morphologicalchanges. The symptoms appeared at least 6 months before diagnosis, and the abovediagnostic criteria were met in the last 3 months.
- Voluntarily participate in the experiment and sign the informed consent.
Exclusion
Exclusion Criteria:
- Patients with endoscopy examinations which suggest chronic intestinal diseases otherthan IBS, such as inflammatory bowel disease, celiac disease, gastric and duodenalulcers, parasitic or bacterial intestinal infections;
- Pregnant and lactating women;
- Patients suffering from serious concomitant diseases, such as liver disease,cardiovascular disease, lung disease, kidney disease, tumor;
- Alcoholism.
Study Design
Total Participants: 150
Treatment Group(s): 2
Primary Treatment: Placebo
Phase: 4
Study Start date:
November 01, 2023
Estimated Completion Date:
November 30, 2024
Connect with a study center
Zhenyu Zhang
Nanjing, Jiangsu 210000
ChinaSite Not Available

Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.